Partner at Shearman & Sterling LLP
Jordan Altman is a partner in the IP transactions group of Shearman & Sterling LLP in New York.
He practises corporate law with an emphasis on structuring, drafting and negotiating agreements that focus on the development, transfer, procurement, commercialisation and maintenance of intellectual property and technology. He also counsels clients, including public companies, growing technology-driven businesses and start-ups, on IP portfolio development. He has extensive experience working with clients in the pharmaceutical, medical device, chemical, entertainment, sports, automotive, software and financial services industries.
Prior to joining Shearman & Sterling, Mr Altman practised patent and trademark prosecution for pharmaceutical and medical device companies and participated in patent and trade secret litigation. He also examined patent applications for inventions relating to immunological functions at the US Patent and Trademark Office before obtaining his law degree.
Mr Altman has been recognised as a “Top Intellectual Property Lawyer in North America” by MergerLinks (2019) and is a recommended attorney in IAM Patent 1000 (2019 and 2020). Mr Altman's recent notable transactions include his work representing the Dow Chemical Company in connection with its $130 billion separation and spin-off from DowDuPont; Raytheon in connection with its $120 billion merger of equals with United Technologies Corporation; and CVS Health Corporation in its $69 billion acquisition of Aetna Inc.